{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:43:17Z","timestamp":1775043797899,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.4158\/ep13020.ra","type":"journal-article","created":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T21:01:43Z","timestamp":1370984503000},"page":"821-828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Autoimmune Thyroid Disease in the Use of Alemtuzumab for Multiple Sclerosis: A Review"],"prefix":"10.1016","volume":"19","author":[{"given":"Algenes Alphius","family":"Aranha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saima","family":"Amer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham Saleh","family":"Reda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon A.","family":"Broadley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Davoren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP13020.RA_bb0010","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.4158\/EP13020.RA_bb0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/146532401753174098","article-title":"The CD52 antigen and development of the CAMPATH antibodies","volume":"3","author":"Hale","year":"2001","journal-title":"Cytotherapy"},{"key":"10.4158\/EP13020.RA_bb0020","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/eji.1830210714","article-title":"Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone","volume":"21","author":"Xia","year":"1991","journal-title":"Eur J Immunol"},{"key":"10.4158\/EP13020.RA_bb0025","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia","volume":"15","author":"Osterborg","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP13020.RA_bb0030","first-page":"813","article-title":"Elimination of graft versus host disease in matched allogeneic leukemic transplant recipients using CAMPATH-1","volume":"186","author":"Slavin","year":"1985","journal-title":"Adv Exp Med Biol"},{"key":"10.4158\/EP13020.RA_bb0035","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.4158\/EP13020.RA_bb0040","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.4158\/EP13020.RA_bb0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP13020.RA_bb0050","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#","article-title":"Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis","volume":"46","author":"Coles","year":"1999","journal-title":"Ann Neurol"},{"key":"10.4158\/EP13020.RA_bb0055","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"New Engl J Med"},{"key":"10.4158\/EP13020.RA_bb0060","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","article-title":"Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial","volume":"78","author":"Coles","year":"2012","journal-title":"Neurology"},{"key":"10.4158\/EP13020.RA_bb0065","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","article-title":"Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis","volume":"354","author":"Coles","year":"1999","journal-title":"Lancet"},{"key":"10.4158\/EP13020.RA_bb0070","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"Cossburn","year":"2011","journal-title":"Neurology"},{"key":"10.4158\/EP13020.RA_bb0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1468-1331.2011.03507.x","article-title":"A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis","volume":"19","author":"Fox","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.4158\/EP13020.RA_bb0080","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/BF03348040","article-title":"Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis","volume":"21","author":"Rotondi","year":"1998","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/EP13020.RA_bb0085","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1586\/ern.12.5","article-title":"Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis","volume":"12","author":"Costelloe","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"10.4158\/EP13020.RA_bb0090","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/ard.2007.081661","article-title":"Long-term follow-up of relapsing\/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)","volume":"67","author":"Walsh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.4158\/EP13020.RA_bb0095","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood-2002-04-1093","article-title":"Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation","volume":"101","author":"Ratzinger","year":"2003","journal-title":"Blood"},{"key":"10.4158\/EP13020.RA_bb0100","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"key":"10.4158\/EP13020.RA_bb0105","first-page":"1522","article-title":"Effects of CAMPATH-1 antibodies on the functional activity of monocytes and polymorphonuclear neutrophils","volume":"21","author":"Fabian","year":"1993","journal-title":"Exp Hematol"},{"key":"10.4158\/EP13020.RA_bb0110","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.beem.2009.07.003","article-title":"Immune reconstitution syndrome and the thyroid","volume":"23","author":"Weetman","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.4158\/EP13020.RA_bb0115","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/sj.bmt.1703291","article-title":"Relapse of Graves\u2019 disease after successful allogeneic bone marrow transplantation","volume":"28","author":"Hsiao","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.4158\/EP13020.RA_bb0120","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(05)60398-4","article-title":"Delayed occurrence of Graves\u2019 disease after immune restoration with HAART. Highly active antiretroviral therapy","volume":"352","author":"Gilquin","year":"1998","journal-title":"Lancet"},{"key":"10.4158\/EP13020.RA_bb0125","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2012.04008.x","article-title":"Lymphodepletion and homeostatic proliferation: implications for transplantation","volume":"12","author":"Tchao","year":"2012","journal-title":"Am J Transplant"},{"key":"10.4158\/EP13020.RA_bb0130","first-page":"362","article-title":"Thyroiditis in T cell-depleted rats. Influence of strain, radiation dose, adjuvants and antilymphocyte serum","volume":"21","author":"Penhale","year":"1975","journal-title":"Clin Exp Immunol"},{"key":"10.4158\/EP13020.RA_bb0135","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.nrl.0000162956.40653.38","article-title":"Multiple sclerosis and Hashimoto thyroiditis: two cases","volume":"11","author":"Petek-Balci","year":"2005","journal-title":"Neurologist"},{"key":"10.4158\/EP13020.RA_bb0140","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1089\/thy.1997.7.743","article-title":"Opposite changes in serum soluble CD8 in patients at the active stages of Graves' and Hashimoto's diseases","volume":"7","author":"Watanabe","year":"1997","journal-title":"Thyroid"},{"key":"10.4158\/EP13020.RA_bb0145","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1084\/jem.177.3.627","article-title":"Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential","volume":"177","author":"Fowell","year":"1993","journal-title":"J Exp Med"},{"key":"10.4158\/EP13020.RA_bb0150","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1046\/j.1365-2249.2002.01818.x","article-title":"The effects of CD40- and interleukin (IL-4)-activated CD23+ cells on the production of IL-10 by mononuclear cells in Graves' disease: the role of CD8+ cells","volume":"128","author":"Uchimura","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.4158\/EP13020.RA_bb0155","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/brain\/123.6.1102","article-title":"Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey","volume":"123","author":"Broadley","year":"2000","journal-title":"Brain"},{"key":"10.4158\/EP13020.RA_bb0160","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1054\/jocn.2000.0693","article-title":"The occurrence of autoimmune diseases in patients with multiple sclerosis and their families","volume":"7","author":"Henderson","year":"2000","journal-title":"J Clin Neurosci"},{"key":"10.4158\/EP13020.RA_bb0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1740-2557-2-9","article-title":"Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort","volume":"2","author":"Sloka","year":"2005","journal-title":"J Autoimmune Dis"},{"key":"10.4158\/EP13020.RA_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000341902","article-title":"Modelling genetic susceptibility to multiple sclerosis with family data","volume":"40","author":"O\u2019Gorman","year":"2013","journal-title":"Neuroepidemiology"},{"key":"10.4158\/EP13020.RA_bb0175","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1002\/ana.410360706","article-title":"Human leukocyte antigen studies in multiple sclerosis","volume":"36","author":"Hillert","year":"1994","journal-title":"Ann Neurol"},{"key":"10.4158\/EP13020.RA_bb0180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/10507250150500630","article-title":"Association of the HLA-DRB1*0301 and HLA-DQA1*0501 alleles with Graves\u2019 disease in a population representing the gene contribution from several ethnic backgrounds","volume":"11","author":"Maciel","year":"2001","journal-title":"Thyroid"},{"key":"10.4158\/EP13020.RA_bb0185","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.gene.6364375","article-title":"A CD40 Kozak sequence polymorphism and susceptibility to antibody-mediated autoimmune conditions: the role of CD40 tissue-specific expression","volume":"8","author":"Jacobson","year":"2007","journal-title":"Genes Immun"},{"key":"10.4158\/EP13020.RA_bb0190","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/ng.396","article-title":"Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20","volume":"41","year":"2009","journal-title":"Nat Genet"},{"key":"10.4158\/EP13020.RA_bb0195","doi-asserted-by":"crossref","first-page":"e1000369","DOI":"10.1371\/journal.pgen.1000369","article-title":"Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D","volume":"5","author":"Ramagopalan","year":"2009","journal-title":"PLoS Genet"},{"key":"10.4158\/EP13020.RA_bb0200","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/thy.2000.10.475","article-title":"Vitamin D receptor initiation codon polymorphism in Japanese patients with Graves\u2019 disease","volume":"10","author":"Ban","year":"2000","journal-title":"Thyroid"},{"key":"10.4158\/EP13020.RA_bb0205","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2265.2007.02762.x","article-title":"Association of the interleukin-2 receptor alpha (IL-2Ralpha)\/CD25 gene region with Graves\u2019 disease using a multilocus test and tag SNPs","volume":"66","author":"Brand","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP13020.RA_bb0210","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa073493","article-title":"Risk alleles for multiple sclerosis identified by a genomewide study","volume":"357","author":"Hafler","year":"2007","journal-title":"N Eng J Med"},{"key":"10.4158\/EP13020.RA_bb0215","first-page":"2052","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J Clin Invest"},{"key":"10.4158\/EP13020.RA_bb0220","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","author":"Sawcer","year":"2011","journal-title":"Nature"},{"key":"10.4158\/EP13020.RA_bb0225","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJM200010263431707","article-title":"Graves\u2019 disease","volume":"343","author":"Weetman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.4158\/EP13020.RA_bb0230","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/thy.2012.0374","article-title":"Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa","volume":"23","author":"McLachlan","year":"2013","journal-title":"Thyroid"},{"key":"10.4158\/EP13020.RA_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","article-title":"Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review","volume":"167","author":"Juszczak","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP13020.RA_bb0240","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.4158\/EP13020.RA_bb0245","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1089\/thy.2010.1635","article-title":"Drugs affecting thyroid function","volume":"20","author":"Barbesino","year":"2010","journal-title":"Thyroid"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20446488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20446488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/L974802L039T600L.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:54:31Z","timestamp":1761515671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20446488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1530891X20446488"],"URL":"https:\/\/doi.org\/10.4158\/ep13020.ra","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune Thyroid Disease in the Use of Alemtuzumab for Multiple Sclerosis: A Review","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP13020.RA","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}